BG104537A - 1,3-doublesubstituted carbamides as acat inhibitors and method for their preparation - Google Patents

1,3-doublesubstituted carbamides as acat inhibitors and method for their preparation

Info

Publication number
BG104537A
BG104537A BG104537A BG10453700A BG104537A BG 104537 A BG104537 A BG 104537A BG 104537 A BG104537 A BG 104537A BG 10453700 A BG10453700 A BG 10453700A BG 104537 A BG104537 A BG 104537A
Authority
BG
Bulgaria
Prior art keywords
carbamides
preparation
doublesubstituted
acat inhibitors
isocyanates
Prior art date
Application number
BG104537A
Other languages
Bulgarian (bg)
English (en)
Inventor
Vladimir Oremus
Vendelin Smahovsky
Viera Faberova
Ivan Kakalik
Ludmila Schmidtova
Marian Zemanek
Original Assignee
Slovakofarma, A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Slovakofarma, A.S. filed Critical Slovakofarma, A.S.
Publication of BG104537A publication Critical patent/BG104537A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C275/36Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43Y being a hetero atom
    • C07C323/44X or Y being nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
BG104537A 1997-12-19 2000-06-15 1,3-doublesubstituted carbamides as acat inhibitors and method for their preparation BG104537A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SK1751-97A SK282727B6 (sk) 1997-12-19 1997-12-19 1,3-Disubstituované močoviny - inhibítory ACAT a spôsob ich prípravy
PCT/SK1998/000019 WO1999032437A1 (en) 1997-12-19 1998-12-16 1,3-disubstituted ureas as acat inhibitors, and method of preparing thereof

Publications (1)

Publication Number Publication Date
BG104537A true BG104537A (en) 2000-12-29

Family

ID=20434795

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104537A BG104537A (en) 1997-12-19 2000-06-15 1,3-doublesubstituted carbamides as acat inhibitors and method for their preparation

Country Status (18)

Country Link
US (1) US6444691B1 (de)
EP (1) EP1042278B1 (de)
JP (1) JP2001526259A (de)
AT (1) ATE233727T1 (de)
AU (1) AU1697699A (de)
BG (1) BG104537A (de)
CZ (1) CZ299695B6 (de)
DE (1) DE69811949T2 (de)
DK (1) DK1042278T3 (de)
ES (1) ES2194379T3 (de)
HR (1) HRP20000351B1 (de)
HU (1) HUP0004332A3 (de)
PL (1) PL341235A1 (de)
PT (1) PT1042278E (de)
RU (1) RU2216536C2 (de)
SK (1) SK282727B6 (de)
WO (1) WO1999032437A1 (de)
YU (1) YU35100A (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション p38キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
AU2003209118A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2005068420A1 (en) * 2003-12-23 2005-07-28 Esperion Therapeutics, Inc. Urea and thiourea compounds and compositions for cholesterol management and related uses
JP2007532484A (ja) 2004-03-16 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法
EP1814875A4 (de) 2004-10-20 2010-02-17 Univ California Verbesserte inhibitoren der löslichen epoxidhydrolase
SK287385B6 (sk) 2007-11-27 2010-08-09 Hameln-Rds, A. S. 1,3-Disubstituované močoviny, spôsob ich prípravy a použitia
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
CA2791680A1 (en) * 2010-03-01 2011-09-09 Myrexis, Inc. Compounds and therapeutic uses thereof
RU2486893C1 (ru) * 2012-06-13 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный технический университет" (ВолгГТУ) Способ получения бис[3-метил(адамант-1-ил)]мочевин
CN107417478B (zh) * 2017-06-05 2020-05-05 南京师范大学 一种催化氧化羰基化合成不对称二取代脲的方法
CN115677660B (zh) * 2022-10-27 2024-05-03 中国药科大学 苯基脲类化合物及其制备方法、用途和药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3284433A (en) * 1963-07-17 1966-11-08 Merck & Co Inc 4-phenoxy-carbanilides
FR1593586A (de) * 1967-10-17 1970-06-01
DE2246109A1 (de) * 1972-09-20 1974-03-28 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazinderivate, ein verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
JP2720053B2 (ja) * 1988-11-09 1998-02-25 チッソ株式会社 新規なジアミノ化合物、ジニトロ化合物、ジオール化合物および製造方法
FR2674522B1 (fr) 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
US5576335A (en) 1994-02-01 1996-11-19 Nisshin Flour Milling Co., Ltd. Urea derivatives and their use as ACAT inhibitors
JP3668266B2 (ja) 1994-02-01 2005-07-06 株式会社日清製粉グループ本社 尿素誘導体
CA2161376C (en) 1994-10-27 2005-01-11 Toshiaki Minami Reversible multi-color thermal recording medium

Also Published As

Publication number Publication date
AU1697699A (en) 1999-07-12
HRP20000351B1 (en) 2003-10-31
HUP0004332A3 (en) 2002-11-28
RU2216536C2 (ru) 2003-11-20
DK1042278T3 (da) 2003-06-30
US6444691B1 (en) 2002-09-03
DE69811949D1 (de) 2003-04-10
EP1042278B1 (de) 2003-03-05
CZ299695B6 (cs) 2008-10-22
PL341235A1 (en) 2001-03-26
SK175197A3 (en) 1999-07-12
HUP0004332A2 (hu) 2001-05-28
WO1999032437A1 (en) 1999-07-01
CZ20002297A3 (cs) 2000-11-15
DE69811949T2 (de) 2004-03-04
HRP20000351A2 (en) 2000-12-31
SK282727B6 (sk) 2002-11-06
PT1042278E (pt) 2003-07-31
YU35100A (sh) 2002-10-18
JP2001526259A (ja) 2001-12-18
EP1042278A1 (de) 2000-10-11
ES2194379T3 (es) 2003-11-16
ATE233727T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
BG104537A (en) 1,3-doublesubstituted carbamides as acat inhibitors and method for their preparation
IL127897A (en) Hamster ef-1alpha transcriptional regulatory dna
MX9702204A (es) Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)].
WO1997026270A3 (en) Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
FI972992A (fi) In vitro -menetelmä templaattien tuottamiseksi DNA-sekventointia varten
GB9907813D0 (en) Synthesis
DE69425940D1 (de) Enzymatische synthese von ceramiden und hybrid-ceramiden
ATE246516T1 (de) Neue enzyme und prodrugs für adept
DE59907222D1 (de) Verfahren zur herstellung von geschäumten polyisocyanat-polyadditionsprodukten oder polyurethanelastomeren unter verwendung von mischungen enthaltend isocyanate sowie organische und/oder anorganische säureanhydride
DE69431564D1 (de) Reagenz zur behandlung von arthritischen zustaenden
DE69920492D1 (de) Staubarme antioxidans-pellets von ausgewogener härte und prozess zur produktion selbiger
BR9813079A (pt) Processo para a preparação de um antibiótico beta-lactama
PT904348E (pt) Processo para a producao de aminoalcoois e seus derivados
ATE391117T1 (de) Verfahren zur herstellung von 4-aminodiphenylamin-zwischenprodukten
CY1109586T1 (el) Επεξεργασια λιγνοκυτταρινουχων υποστρωματων με οζον
PT1019347E (pt) Metodo para a sintese de taxanos
DE3679455D1 (de) H2o2-bildende sarcosinoxidase, ihre herstellung und verwendung.
AU2002361162A8 (en) Evanescence-based multiplex sequencing method
SU1811161A1 (ru) Способ получения органических изоцианатов
HUP0104214A2 (hu) Javított eljárás alfa-klór-nitrilek előállítására
MD990158A (ro) Procedeu de preparare a clorhidratului de 2-clor-4-dimetil-amidosulfonil-fenoxiacetat de N,N-dimetilaminoetanol
DE69938427D1 (de) Tes gen und dessen verwendung
DE50005001D1 (de) Verfahren zur Absenkung des Chlorgehaltes von niedermolekularen Isocyanaten
ATE191508T1 (de) Mikrobiologisches verfahren zur herstellung von 1-ungesättigten, 17-beta-carboxysubstituierten 3- oxo-4-azaandrostan-3-onen
HUP9901872A2 (hu) Eljárás optikailag aktív cianohidrinszármazékok előállítására